A Risk Benefit Assessment of Drugs Used in the Treatment of Endometriosis

Robert W. Shaw, R W Shaw
Drug safety · 1994 · vol. 11(2) , pp. 104–113 · doi:10.2165/00002018-199411020-00005 · PMID:7945998 · W1970671347
review OA: closed CC0 ⤵ 9 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-06 ⓘ

Progestogens and GnRH agonists can reduce endometriosis symptoms, but GnRH agonists cause bone loss, limiting long-term use without add-back therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 ⓘ

This paper reviews how hormonal medical treatments for endometriosis target the hormonal dependence of endometriotic implants, focusing on progestogens, gestrinone, and newer GnRH agonists compared in clinical trials to danazol. It reports that GnRH agonists in novel formulations significantly reduce symptoms during treatment and for 6–12 months after, with comparable improvements in R-AFS scores and fewer discontinuations than danazol, while long-term use is limited by hypoestrogenism-related bone mineral metabolism changes analogous to menopause. A stated major caveat is that there are few long-term follow-up data for gestrinone, and GnRH agonist duration is constrained until effective bone-protective add-back regimens are developed. This paper is centrally about endometriosis — it assesses the risk-benefit of drug classes (progestogens, gestrinone, and GnRH agonists) used to treat endometriosis and discusses efficacy versus limitations such as bone loss.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Cyclooxygenase Inhibitors Endometriosis Gonadal Steroid Hormones Gonadal Steroid Hormones Cyclooxygenase Inhibitors Endometriosis Endometriosis Female Gonadal Steroid Hormones Humans Risk Assessment

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (9)

SciLite annotations

chemicals 7
gestrinone danazol danazol danazol biliverdin beta estradiol mineral

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:24.284338+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
unpaywall
last seen: 2026-06-14T06:15:46.576397+00:00
License: CC0 · commercial use OK